Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives $27.33 Consensus Price Target from Brokerages

Key Points

• Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has received an average analyst recommendation of "Moderate Buy," with one hold rating and five buy ratings from six analysts covering the stock.
• The average twelve-month target price set by brokerages for KMTS is $27.33, although Wells Fargo recently adjusted their price target down from $28.00 to $27.00 while maintaining an "overweight" rating.
• Institutional investors have shown significant interest, with multiple firms recently acquiring new positions in Kestra, including Virtu Financial LLC investing approximately $210,000 in the first quarter.

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $27.3333.

Several equities research analysts have weighed in on the company. Wells Fargo & Company cut their price target on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating on the stock in a research report on Thursday, July 17th. Wall Street Zen upgraded shares of Kestra Medical Technologies from a "sell" rating to a "hold" rating in a research report on Saturday.

Kestra Medical Technologies Stock Up 2.4%

NASDAQ KMTS traded up $0.61 during trading hours on Monday, hitting $25.55. 302,768 shares of the company were exchanged, compared to its average volume of 356,226. Kestra Medical Technologies has a 52 week low of $13.25 and a 52 week high of $27.71. The stock has a 50-day moving average price of $17.53 and a 200 day moving average price of $20.02. The company has a current ratio of 6.84, a quick ratio of 6.84 and a debt-to-equity ratio of 0.23.

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP acquired a new stake in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $33,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Kestra Medical Technologies during the 2nd quarter worth approximately $54,000. New York State Common Retirement Fund purchased a new stake in Kestra Medical Technologies in the 2nd quarter valued at $93,000. Walleye Capital LLC purchased a new stake in Kestra Medical Technologies in the 2nd quarter worth about $166,000. Finally, Rhumbline Advisers bought a new stake in shares of Kestra Medical Technologies during the 2nd quarter valued at about $200,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.